New diet pill no easy path to weight loss
Experts are skeptical that Belviq, the first weight-loss treatment approved by the FDA in more than a decade, is worth the bother.
For one thing, Belviq has a host of side effects ranging from dizziness to heart valve problems to painful erections. To make matters worse, patients have to take Belviq for the rest of their lives and it carries a hefty wholesale price of $200 per month. The results achieved by Belviq, which the FDA has approved for adults who are overweight and also suffer from diabetes or other serious medical conditions, are nothing special either.
"In a study, the average weight loss over the course of a year using Belviq was 3.7% more of a person’s total body weight than the patients on placebo," according to The Los Angeles Times, adding that's a loss of fewer than 10 pounds for a 250-pound person. "That sort of loss could be easily achieved by mild changes in eating and exercise habits."
Consumer Reports, which is advising people to take a pass on Belviq, said patients in one trial lost up to 5% of their body weight after 12 months but regained 25% of it by the end of the second year.
For its part, Arena said Belviq has been proven to be safe and effective.
The costs associated with obesity are astounding, some $190 billion a year, or more than 20% of U.S. health care expenditures.
Unfortunately, for many there are no shortcuts to losing weight.
--Jonathan Berr does not own shares of the listed stocks. Follow him on Twitter @jdberr.
- How the Affordable Care Act becomes unaffordable
- Showdown looms over 'bring your guns to work' laws
- DirecTV gets burned over Colorado fire fees
This author needs to go back and read the specs from the FDA label, Jonathon Berr is 100% inaccurate on this piece. Also, he needs to read what the American Association of Clinical Endocrinology endorsement says about new "novel" weight lose medication options.
Oh, did I mention that Belviq is a new "Novel" Rx. The first new "Novel" Obesity Rx approved in 13 years, with "No' REMS.
what an ignorant statement. The FDA determined Belviq to be safe and effective.
8% completer efficacy / 12% responder efficacy in a year - excellent safety profile. Poor short sellers. No article is going to help them.
Copyright © 2014 Microsoft. All rights reserved.
[BRIEFING.COM] The headlines generally favored Tuesday being another good day for the stock market. Instead, it was just a mixed day with modest point changes on either side of the unchanged mark for the major indices.
For the most part, the stock market was a sideshow. The main trading events were seen in the commodity and Treasury markets, both of which saw some decent-sized losses within their respective complex.
Dollar strength was at the heart of the weakness in ... More
More Market News
The S&P 500 manages to keep a deathgrip on 2,000, but key areas of the market are already buckling under pressure.
MUST-SEE ON MSN
A charcuterie master shares his process for cold-smoking meat at home.
- Jetpacks about to go mainstream
- Weird things covered by home insurance
- Bing: 70 percent of adults report 'digital eye strain'